Literature DB >> 10543770

In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

P M Roblin1, T Reznik, A Kutlin, M R Hammerschlag.   

Abstract

We compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10543770      PMCID： PMC89566     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.

Authors:  J I Oh; K S Paek; M J Ahn; M Y Kim; C Y Hong; I C Kim; J H Kwak
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

Authors:  M G Cormican; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors:  S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129
  8 in total
  3 in total

Review 1.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Gemifloxacin.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

3.  Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes.

Authors:  I García; A Pascual; S Ballesta; P Joyanes; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.